Exploring the safety of combination therapy with SGLT-2 and DPP-4 inhibitors in type 2 Diabetes mellitus
Abstract
Type 2 diabetes mellitus (T2DM) presents a complex pathogenesis involving various mechanisms, necessitating multiple therapeutic approaches for effective glycemic control. While metformin remains the first-line therapy, additional agents are often required to maintain optimal glucose levels. The combinatory use of anti-diabetic agents with complementary mechanisms of action, such as sodium-glucose co-transporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors, has emerged as a promising strategy. This review explores the safety profile of different combinations of SGLT2 inhibitors and DPP4 inhibitors. SGLT2 inhibitors offer glucose-lowering effects with potential cardiovascular benefits but come with considerations such as the risk of hypoglycemia, urinary tract and genital infections, diabetic ketoacidosis, and fractures and amputations. Conversely, DPP-4 inhibitors provide effective glycemic control with a low risk of hypoglycemia, although concerns exist regarding infections, hypersensitivity reactions, pancreatitis, and cardiovascular safety. Evaluating combination therapies, including Empagliflozin + Linagliptin, Canagliflozin + Teneligliptin, Dapagliflozin + Saxagliptin, and Dapagliflozin + Sitagliptin, reveals a generally favorable safety profile, with manageable risks consistent with individual component therapies. Notably, these combinations mitigate the risk of hypoglycemia while offering efficacy in glycemic control. Further research and monitoring are warranted to fully elucidate the long-term safety and efficacy of these combination therapies in managing T2DM.
References
Defronzo, R. A. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58, 773–795, https://doi.org/10.2337/db09-9028 (2009).
2. Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., ... & Buse, J. B. (2022). Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 65(12), 1925-1966.
3.
Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–2443
4.
Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005–2012
5.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–1589
6.
DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis:a new path towards normalizing glycaemia. Diabetes Obes Metab 2012;14:5–14
7.
Barnett AH. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. Postgrad Med 2013;125:92–100
8.
Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014;8:262–275, e9
9.
Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008;4:753–768
10.
Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369
11. Mascolo, A., Di Napoli, R., Balzano, N., Cappetta, D., Urbanek, K., De Angelis, A., ... & Sportiello, L. (2022). Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary. Frontiers in Cardiovascular Medicine, 9, 1010693 Karagiannis, T., Boura, P., & Tsapas, A. (2014).
12. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Therapeutic advances in drug safety, 5(3), 138-146
13. DeFronzo, R. A., Lewin, A., Patel, S., Liu, D., Kaste, R., Woerle, H. J., & Broedl, U. C. (2015). Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes care, 38(3), 384-393.
14. Lewin, A., DeFronzo, R. A., Patel, S., Liu, D., Kaste, R., Woerle, H. J., & Broedl, U. C. (2015). Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes care, 38(3), 394-402.
15. Søfteland E, Meier JJ, Vangen B, Toorawa R, Maldonado-Lutomirsky M, Broedl UC. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial. Diabetes Care. 2017 Feb;40(2):201-209. doi: 10.2337/dc16-1347. Epub 2016 Dec 2. PMID: 27913576.
16. Kadowaki, T., Inagaki, N., Kondo, K., Nishimura, K., Kaneko, G., Maruyama, N., ... & Gouda, M. (2017). Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in J apanese patients with type 2 diabetes mellitus: R esults of a 24‐week, randomized, double‐blind, placebo‐controlled trial. Diabetes, Obesity and Metabolism, 19(6), 874-882.
17. Rosenstock, J., Hansen, L., Zee, P., Li, Y., Cook, W., Hirshberg, B., & Iqbal, N. (2015). Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes care, 38(3), 376-383.
18. Mathieu, C., Ranetti, A. E., Li, D., Ekholm, E., Cook, W., Hirshberg, B., ... & Iqbal, N. (2015). Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes care, 38(11), 2009-2017.
